Body Systems

Breast Cancer3 Results found

Closed for recruitment:

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a…

This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of Kadcyla (trastuzumab emtansine, also known as T-DM1) in combination with Perjeta (pertuzumab) versus Herceptin (trastuzumab) in combination with Perjeta and a taxane as adjuvant therapy in patients wi

Closed for Recruitment
Principal Investigator 
Sasha Smiljanic
Body Locations and Systems 
Breast Cancer
Area 
North Vancouver
Age 
18 and above

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a…

This two-arm, randomized, open-label, multicenter study will evaluate the effica cy and safety of Kadcyla (trastuzumab emtansine, also known as T-DM1) in combina tion with Perjeta (pertuzumab) versus Herceptin (trastuzumab) in combination wit h Perjeta and a taxane as adjuvant therapy in patients

Closed for Recruitment
Principal Investigator 
Stephen Chia
Body Locations and Systems 
Breast Cancer
Area 
Vancouver
Age 
18 and above

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

The purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor and are not Her2 amplified.

Closed for Recruitment
Principal Investigator 
Karen A. Gelmon
Body Locations and Systems 
Breast Cancer
Area 
Vancouver
Age 
18 and above